Fig. 6: CDX0239-PBD demonstrates potent in vivo antitumor activity in ALK-expressing xenograft models. | Nature Communications

Fig. 6: CDX0239-PBD demonstrates potent in vivo antitumor activity in ALK-expressing xenograft models.

From: A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

Fig. 6

A Average tumor volume in neuroblastoma xenograft models NB-1, NB-SD, COG-N-424x, SK-N-AS, and NGP ALK wild-type (WT) with 3 weekly treatments of 1 mg/kg CDX0239-PBD (blue line with circles) compared to IgG (gray line with squares) and normal saline vehicle (black line with circles). B Average tumor volume of colorectal carcinoma xenograft models HCT-116 and SW-48 and fusion-positive rhabdomyosarcoma xenograft model RH-41 with 3 weekly treatments of 1 mg/kg CDX0239-PBD (blue line with circles) compared to IgG (gray line with squares) and normal saline vehicle (black line with circles). C Average tumor volume in neuroblastoma xenograft model NB-1 with a single 1 mg/kg dose of CDX0239-PBD (blue line with circles) compared normal saline vehicle (black line with circles). D Average tumor volume in neuroblastoma xenograft model NGP ALK knockout (KO) with 3 weekly treatments of 1 mg/kg CDX0239-PBD (blue line with circles) compared to IgG (gray line with squares) and normal saline vehicle (black line with circles). All data are plotted as mean ± standard deviation with n = 5 mice per treatment condition for all experiments, and each experiment was completed once. All p-values represent CDX0239-PBD vs vehicle tumor volumes using a square root transformation analysis with linear mixed effects model. Exact p-values and datasets are located within the Source Data file. Source data are provided as a Source Data file.

Back to article page